1. Home
  2. TGLS vs SRPT Comparison

TGLS vs SRPT Comparison

Compare TGLS & SRPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Tecnoglass Inc.

TGLS

Tecnoglass Inc.

HOLD

Current Price

$35.99

Market Cap

1.9B

ML Signal

HOLD

Logo Sarepta Therapeutics Inc. (DE)

SRPT

Sarepta Therapeutics Inc. (DE)

HOLD

Current Price

$20.75

Market Cap

2.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TGLS
SRPT
Founded
1984
1980
Country
United States
United States
Employees
N/A
N/A
Industry
Electronic Components
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.9B
2.0B
IPO Year
2011
2000

Fundamental Metrics

Financial Performance
Metric
TGLS
SRPT
Price
$35.99
$20.75
Analyst Decision
Strong Buy
Hold
Analyst Count
3
29
Target Price
$63.33
$25.85
AVG Volume (30 Days)
238.3K
3.0M
Earning Date
05-07-2026
05-06-2026
Dividend Yield
1.41%
N/A
EPS Growth
N/A
N/A
EPS
1.27
2.99
Revenue
$370,984,000.00
$2,198,237,000.00
Revenue This Year
$13.56
N/A
Revenue Next Year
$9.04
N/A
P/E Ratio
$30.17
$6.84
Revenue Growth
17.98
15.58
52 Week Low
$37.35
$14.68
52 Week High
$71.84
$25.32

Technical Indicators

Market Signals
Indicator
TGLS
SRPT
Relative Strength Index (RSI) 33.83 54.93
Support Level N/A $20.12
Resistance Level $46.99 $23.70
Average True Range (ATR) 1.44 1.55
MACD -0.11 -0.14
Stochastic Oscillator 0.88 50.28

Price Performance

Historical Comparison
TGLS
SRPT

About TGLS Tecnoglass Inc.

Tecnoglass Inc is a manufacturer of hi-spec architectural glass and windows for residential and commercial construction industries, operating through its direct and indirect subsidiaries. Its product offerings include tempered glass, laminated glass, thermo-acoustic glass, sliding windows, projecting windows, guillotine windows, sliding doors, loating facades, automatic doors, bathroom dividers, and commercial display windows, among others. The company has one operating segment, Architectural Glass and Windows, which is also its reporting segment. Geographically, the company generates maximum revenue from its customers in the United States, followed by Colombia, Panama, and other regions.

About SRPT Sarepta Therapeutics Inc. (DE)

Sarepta Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, gene therapies, and other genetic medicines for rare diseases, particularly neuromuscular disorders. The company has developed approved treatments for Duchenne muscular dystrophy, including EXONDYS 51, VYONDYS 53, AMONDYS 45, and ELEVIDYS, and is advancing additional therapeutic candidates for neuromuscular and other rare diseases. The company operates in one segment: discovering, developing, manufacturing, and delivering therapies to patients with rare diseases.

Share on Social Networks: